08048035968
Darzalex 400mg/20ml Good Quality Injection to UK - London | Phoenix Exim | Trusted Exporter

1. General Information

Darzalex 400 mg/20 mL Injection is an oncology medicine containing daratumumab, a CD38-directed monoclonal antibody. It is primarily used as part of treatment regimens for adults with multiple myeloma and, in appropriate patients, systemic light-chain (AL) amyloidosis. Darzalex is a prescription medicine and should be administered under the supervision of a qualified healthcare professional.

Phoenix Exim is a medicine exporter based in Nagpur, India, supplying pharmaceutical products for international markets including the USA, UK, Australia, Singapore, Canada, South Korea and UAE, subject to applicable import, prescription and regulatory requirements.

2. Product Information

  • Brand name: Darzalex
  • Active ingredient: Daratumumab
  • Strength: 400 mg/20 mL
  • Concentration: 20 mg/mL
  • Dosage form: Injection / concentrate for solution for infusion
  • Drug class: Monoclonal antibody / antineoplastic agent
  • Mechanism classification: CD38-directed cytolytic antibody
  • Route: Intravenous infusion for the 400 mg/20 mL presentation
  • Manufacturer/marketing authorisation: Darzalex is associated with Janssen-Cilag International N.V.

The recommended dose of intravenous Darzalex in the U.S. prescribing information is generally 16 mg/kg based on actual body weight, with the exact treatment schedule determined by the patient's diagnosis and combination regimen.

3. Uses of Darzalex 400 mg/20 mL Injection

Darzalex is used in adults for several treatment settings involving plasma-cell disorders. Depending on the patient's condition and treatment history, it may be used:

  • For newly diagnosed multiple myeloma
  • For relapsed or refractory multiple myeloma
  • In combination with medicines such as lenalidomide, dexamethasone, bortezomib, pomalidomide, carfilzomib or other approved treatment combinations
  • As monotherapy in selected patients with relapsed/refractory multiple myeloma
  • For selected adults with high-risk smouldering multiple myeloma, according to applicable regulatory approval
  • In combination with cyclophosphamide, bortezomib and dexamethasone for newly diagnosed systemic AL amyloidosis.

The exact indication varies between countries and depends on the patient's clinical circumstances.

4. Benefits of This Medicine

The potential benefits of daratumumab treatment include:

  • Helps target abnormal plasma cells expressing CD38
  • Can produce responses in multiple myeloma
  • May be used in newly diagnosed as well as relapsed/refractory disease depending on the treatment regimen
  • Can be combined with other anti-myeloma medicines to form a comprehensive treatment regimen
  • Provides an additional treatment option for eligible patients whose disease has returned or stopped responding to previous therapies
  • In AL amyloidosis, daratumumab-based treatment can help control the abnormal plasma-cell process responsible for production of disease-associated light chains.

Treatment response varies between patients and should be evaluated by the treating oncology team.

5. Side Effects of Darzalex

Like all medicines, Darzalex can cause side effects. Important possible adverse effects include:

  • Infusion-related reactions
  • Respiratory infections
  • Pneumonia
  • Bronchitis
  • Fever
  • Fatigue
  • Nausea
  • Diarrhoea or constipation
  • Muscle and bone pain
  • Anaemia
  • Neutropenia
  • Thrombocytopenia
  • Peripheral neuropathy
  • Cough
  • Shortness of breath
  • Peripheral oedema
  • Serious infections in some patients.

6. Common Side Effects

Frequently reported side effects include:

  1. Infusion-related reactions
  2. Fatigue or weakness
  3. Nausea
  4. Fever
  5. Cough
  6. Upper respiratory tract infections
  7. Diarrhoea
  8. Constipation
  9. Muscle or bone pain
  10. Low red blood cell counts
  11. Low neutrophil counts
  12. Low platelet counts
  13. Peripheral swelling
  14. Shortness of breath
  15. Peripheral neuropathy.

The frequency and severity of side effects can depend on the combination of medicines being used.

7. How to Use Darzalex 400 mg/20 mL

Darzalex 400 mg/20 mL intravenous injection is not intended for self-administration. It is diluted and administered as an intravenous infusion by trained healthcare professionals.

The prescribing information recommends pre-treatment with appropriate medicines such as corticosteroids, antipyretics and antihistamines to reduce the risk of infusion-related reactions. Post-infusion medication may also be required.

The dose and infusion schedule are determined by:

  • Body weight
  • Diagnosis
  • Previous treatment
  • Combination medicines
  • Treatment phase
  • Patient-specific medical factors

Patients should follow the exact regimen prescribed by their oncologist.

8. How Darzalex Works

Daratumumab is a CD38-directed monoclonal antibody. CD38 is present in high amounts on abnormal plasma cells associated with multiple myeloma.

Daratumumab binds to CD38 on these abnormal cells and activates several immune-mediated mechanisms that help destroy the targeted cells. This reduces the population of malignant plasma cells and can help control the disease.

9. Safety Advice

Important safety considerations include:

  • Darzalex should only be used under appropriate medical supervision.
  • Patients should be monitored for infusion-related reactions, particularly during and after administration.
  • Healthcare professionals should monitor for signs of infection.
  • Blood counts may need regular monitoring because treatment can cause anaemia, neutropenia and thrombocytopenia.
  • Daratumumab can interfere with certain blood compatibility tests, including the indirect Coombs test, which can complicate blood transfusion compatibility testing. Patients should inform healthcare professionals involved in transfusion care that they are receiving or have received daratumumab.
  • Patients should tell their doctor about previous or current infections and all medicines they are taking.
  • Pregnancy, breastfeeding and vaccination decisions should be discussed with the treating healthcare professional.
  • Urgent medical attention may be required for severe breathing difficulty, significant allergic-type reactions, severe infection symptoms or other serious reactions.

The product should be stored, handled and prepared according to the approved product information and applicable cold-chain requirements.

10. FAQs

Q1. What is Darzalex 400 mg/20 mL?
Darzalex 400 mg/20 mL is an intravenous formulation containing 400 mg of daratumumab in 20 mL. It is used in oncology treatment, particularly for multiple myeloma.

Q2. What is the active ingredient in Darzalex?
The active ingredient is daratumumab.

Q3. What is Darzalex used for?
It is used in specific treatment regimens for multiple myeloma and certain patients with systemic AL amyloidosis.

Q4. Is Darzalex a chemotherapy medicine?
Daratumumab is a targeted monoclonal antibody rather than a conventional cytotoxic chemotherapy drug. It targets CD38-expressing cells.

Q5. How is Darzalex 400 mg/20 mL administered?
The 400 mg/20 mL formulation is diluted and administered as an intravenous infusion by healthcare professionals.

Q6. Can Darzalex be used alone?
In certain multiple-myeloma treatment settings, daratumumab can be used as monotherapy; in many other situations it is used in combination with other medicines.

Q7. Can Darzalex affect blood transfusions?
Yes. Daratumumab can interfere with certain blood compatibility tests, so the transfusion service should be informed that the patient is receiving or has received daratumumab.

Q8. Is a prescription required?
Yes. Darzalex is a prescription oncology medicine and should be used only under appropriate medical supervision.

Q9. Who determines the dose?
The treating oncologist determines the dose and schedule according to body weight, disease, treatment regimen and individual patient factors.

Q10. Can Darzalex cause infusion reactions?
Yes. Infusion-related reactions can occur, which is why patients are monitored and receive preventive medicines around the infusion.

11. Substitute for Darzalex

The appropriate substitute depends on the patient's diagnosis, treatment history, combination regimen and local regulatory approvals. Daratumumab products from different manufacturers may be alternatives only when they are approved, equivalent/appropriate for the intended use, and selected by a healthcare professional.

Other medicines used in multiple myeloma—such as bortezomib, lenalidomide, pomalidomide, carfilzomib, isatuximab or other agents—are not automatically direct substitutes because they have different active ingredients, mechanisms, indications and dosing schedules.

A doctor or oncology pharmacist should determine whether an alternative is clinically appropriate.

12. SEO Keywords

  • Darzalex 400 mg/20 mL Injection exporter
  • Darzalex 400 mg injection supplier India
  • Daratumumab 400 mg/20 mL injection exporter
  • Daratumumab injection supplier from India
  • Darzalex injection pharmaceutical exporter
  • Darzalex 400 mg/20 mL wholesale supplier
  • Daratumumab oncology medicine exporter India
  • Darzalex multiple myeloma medicine supplier
  • Multiple myeloma injection exporter India
  • Daratumumab 400 mg injection supplier Nagpur
  • Darzalex 400 mg/20 mL supplier Nagpur India
  • Oncology medicines exporter from Nagpur
  • Cancer medicine exporter India
  • Daratumumab injection exporter to USA
  • Daratumumab injection exporter to UK
  • Daratumumab injection exporter to Australia
  • Daratumumab injection exporter to Canada
  • Daratumumab injection exporter to Singapore
  • Daratumumab injection exporter to South Korea
  • Daratumumab injection exporter to UAE
  • Darzalex supplier for international markets
  • Daratumumab pharmaceutical supplier India
  • CD38 monoclonal antibody supplier
  • Multiple myeloma medicine wholesale exporter
  • Darzalex 400 mg/20 mL pharmaceutical supplier
  • Daratumumab 20 mg/mL injection supplier
  • Darzalex oncology product supplier
  • Trusted pharmaceutical exporter Nagpur India
  • Phoenix Exim Darzalex supplier
  • Phoenix Exim daratumumab injection exporter
Aug 13th, 2026 2:59 PM

Keywords